“Phase III is in ambulant boys – non ambulant trials not due to commence until sometime 2021 Corticosteroids thought to work through same mechanism (inhibiting NF-Kb) as edasalonexent - unlike ATL1102 which has novel (likely complimentary) mechanism to steroids ”
Anp has a drug in ATL1102 which has a novel mechanism which is complimentary to steroids..
So it’s NOT the same as Edasalonexent.
Itsa posted the above a couple of days ago before Catabasis cancelled their DMD trial...
Im not here to be a Hero and to get multiple likes. I post
my DD for people who want to read it..
My only problem with the Board is when they got their Performance options and interfered with Anpob.(options)
Some here think they know more than our Educated and Experienced Board.. they are indirectly contributing to the negative agenda which is stopping the sp from moving forward...Also the drop with the Dow 600 pts didn’t help our sp yesterday...
Let the Anp Board do their job...PLEASE
DMD results, page-12
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
